Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study (Aug, 10.1038/s41375-021-01371-6, 2021)-MedSci.cn

Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study (Aug, 10.1038/s41375-021-01371-6, 2021)

Yang, Y; Wang, Y; Liu, X; He, X; Zhang, LL; Wu, G; Qu, BL; Qian, LT; Hou, XR; Zhang, FQ; Qiao, XY; Wang, H; Li, GF; Zhu, Y; Cao, JZ; Wu, JX; Wu, T; Zhu, SY; Shi, M; Xu, LM; Su, H; Song, YQ; Zhu, J; Zhang, YJ; Huang, HQ; Hu, C; Qi, SN; Li, YX

LEUKEMIA, 2021; 35 (9): 2736

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study (Aug, 10.1038/s41375-021-01371-6, 2021)

科室

工具

服务